Live Breaking News & Updates on Falk Pharma

Stay updated with breaking news from Falk pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

DelveInsight Business Research, LLP: Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032)

DelveInsight Business Research, LLP: Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-kingdom , United-states , Spain , Italy , Japan , Germany , France , Falk-pharma , Eli-lilly , Selecta-biosciences , Zydus-cadila , Shruti-thakur

Long-term risk of arrhythmias in patients with inflammatory bowel disease: A population-based, sibling-controlled cohort study

In a population-based, sibling-controlled cohort study Jiangwei Sun and colleagues explore the long-term risk of arrhythmias in patients with inflammatory bowel disease. ....

Denmark , China , Montreal , Quebec , Canada , Sweden , North-carolina , United-states , Norway , Texas , Iceland , Finland

Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma

Cosmo Pharmaceuticals N.V. / Key word(s): AgreementTermination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma 04.09.2023 / 05:45 GMT/BSTDublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the termination by mutual agreement of the license with Dr.. ....

Geneva , Genè , Switzerland , Paris , France-general , France , Dublin , Ireland , Hazel-winchester , Falk-pharma , Multi-matrix-technology , Medtronic

Global Dermatology Partnering 2016-2023: Deal Trends, Players and Financials

/PRNewswire/ The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com s offering.. ....

Israel , Grunenthal , Nordrhein-westfalen , Germany , Suzhou , Jiangsu , China , United-kingdom , Berkshire , Massachusetts , United-states , Boston

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

Etrasimod was effective and well tolerated as an induction and maintenance therapy
in patients with moderately to severely active ulcerative colitis. Etrasimod is a
treatment option with a unique combination of attributes that might address the persistent
unmet needs of patients with ulcerative colitis. ....

Boston , Massachusetts , United-states , Western-university , California , San-francisco , Cytoki-pharma , Eli-lilly , Exeliom-biosciences , Vivreon-gastrosciences , Ventyx-biosciences , Oppilan-pharma